Skip to main content
. 2016 May 25;8(8):937–948. doi: 10.15252/emmm.201506083

Figure 6. Antagonism of CXCR2 inhibits enhanced cardiac neutrophil accumulation after ischemia/reperfusion during active phase (ZT13).

Figure 6

  1. Schematic representation of transient ischemia and reperfusion protocol, performed at ZT5 and ZT13. The CXCR2 antagonist SB225002 or vehicle was injected 5 min before reopening the LAD.
  2. Percentage of CXCR2hi neutrophils in the blood 24 h after ZT5 or ZT13 MI in mice receiving CXCR2 antagonist SB225002 or vehicle. Two‐way ANOVA followed by Bonferroni post hoc test; n = 5 mice in both groups at ZT5, n = 5 mice for vehicle, and n = 6 mice for SB225002 at ZT13; DMSO versus SB225002: *P = 0.0046 (ZT13); ZT5 versus ZT13: *P = 0.0153 (DMSO).
  3. Flow cytometric quantification of cardiac neutrophils 24 h after ZT5 or ZT13 MI in mice receiving CXCR2 antagonist SB225002 or vehicle. Two‐way ANOVA; n = 5 mice in both groups at ZT5, n = 5 mice for vehicle, and n = 6 mice for SB225002 at ZT13; DMSO versus SB225002: *P = 0.0006 (ZT13); ZT5 versus ZT13: *P = 0.0001 (DMSO).
  4. Flow cytometric quantification of neutrophils in bone marrow 24 h after ZT5 or ZT13 MI in mice receiving CXCR2 antagonist SB225002 or vehicle. Two‐way ANOVA followed by Bonferroni post hoc test; n = 5 mice in both groups at ZT5, n = 5 mice for vehicle, and n = 6 mice for SB225002 at ZT13; DMSO versus SB225002: *P = 0,0486 (ZT13).
Data information: All data are expressed as mean ± SEM.